Healthy Volunteer Clinical Trial
Official title:
Visual Motor Coordination
Verified date | April 2024 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background: - The relation between eye movement and brain function is a subject of interest to the National Eye Institute. - By comparing eye movement in healthy volunteers to research conducted on patients who have difficulty moving their eyes, the National Eye Institute hopes to develop and improve diagnostic procedures for people with eye diseases. Objectives: -The purpose of this study is to understand how we see visual patterns and how we move our eyes to see. Eligibility: - Normal volunteers: - must have no serious illnesses and must be 18 years of age or older - are able to follow directions and pay attention to visual stimuli and respond as appropriate - individuals with a history of eye or brain diseases, or previous eye or eye muscle surgery, are not allowed to participate in this study. Individuals who are currently using eye medications also are not eligible for the study. - Patients: - who are 18 years of age or older - are able to follow directions and pay attention to visual stimuli and respond as appropriate Design: - Participants will visit the National Eye Institute outpatient clinic for examination and testing. - Participants will be screened with a medical history and eye examination (including eye pressure and eye movement tests). - Participants with healthy eyes will participate in eye movement testing experiments: - One or more sessions lasting less than three hours each. - Eye movements will be recorded with a video/infrared camera system. - For the majority of the studies done under this protocol, only one or two sessions will be required. A few studies recording very small eye movements will require three or more sessions.
Status | Terminated |
Enrollment | 34 |
Est. completion date | April 9, 2024 |
Est. primary completion date | April 9, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | - INCLUSION CRITERIA: Inclusion Criteria for Normal Volunteers: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Participant must be a volunteer with no ocular, visual, or oculomotor problems. 2. Participant must be 18 years old or older. 3. Participant must be able to follow directions and actively pay attention to visual stimuli and respond as appropriate. 4. For studies which use the contact lens, participant must be able to tolerate a contact lens in either one or both eyes. Inclusion Criteria for Patients: In order to be eligible to participate in this study, an individual must meet all of the following criteria 1. Participant must be 18 years old or older. 2. Participant must be able to follow directions and actively pay attention to visual stimuli and respond as appropriate. 3. For studies which use the contact lens, participant must be able to tolerate a contact lens in either one or both eyes. EXCLUSION CRITERIA: Exclusion Criteria for Normal Volunteers: An individual who meets any of the following criteria will be excluded from participation in this study: An individual who meets any of the following criteria will be excluded from participation in thisstudy: 1. Participant has a history of ocular or visual diseases or diseases affecting the nervous system (including myasthenia, MS, etc.) or any diseases which might affect control of eye movements or affect vision. 2. Participant has had prior eye or eye muscle surgery. 3. Participant has a history of eye patching (amblyopia or lazy eye). 4. Participant currently uses eye drops or ocular medications. Exclusion Criteria for Patients: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Patient is unable to cooperate with testing, including sitting still while eye movements are recorded. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Eye Institute (NEI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | eye movement/responses to visual stimuli | Analysis of eye movements to characterize basic processes (normal volunteers) and to judge disease progress (in patients) | one to many times depending if normal volunteer or patient and the number of trials required to achieve clean data for small eye movements. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01579149 -
A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent
|
Phase 1 | |
Completed |
NCT01414881 -
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02547259 -
Influence of Emotion in a Test Run Forgetfulness
|
N/A |